Study Provides Clues for Improving Effectiveness of Flu Vaccine
A new study found that seasonal flu vaccines work better if they stimulate an immune response to the flu surface protein neuraminidase.
Gene Therapy Results in Sustained Factor VIII Expression and Reduced Bleeding Episodes in Dogs with Severe Hemophilia A
Two young adult male dogs with severe hemophilia A treated with liver-targeted gene therapy experienced significant improvement in disease phenotype over follow-up periods of 31 months and 24 months, according to investigators at The Children’s Hospital of Philadelphia and the University of Pennsylvania.
CMS Finalizes 2017 ACA Marketplace Plan Requirements
The Centers for Medicare and Medicaid Services published its annual Notice of Benefit and Payment Parameters, which governs participation in the Affordable Care Act health insurance marketplaces for 2017.
Medicare Rights Launches New Medicare Interactive
The Medicare Rights Center has launched Medicare Interactive (MI), a free online resource with hundreds of answers to Medicare questions.
CDC Issues Guidelines for Prescribing Opioids for Chronic Pain
The Centers for Disease Control and Prevention (CDC) has released the CDC Guideline for Prescribing Opioids for Chronic Pain.
Flu Vaccine Given in the Morning Could Be More Effective
Researchers found that flu vaccines are more effective when given in the morning because patients’ immune systems are capable of producing more antibodies in response to the vaccine in the first part of the day.
FDA Approves First Coagulation Factor-Albumin Fusion Protein to Treat Hemophilia B
In March, the U.S. Food and Drug Administration (FDA) approved CSL Behring’s Idelvion (coagulation factor IX [recombinant], albumin fusion protein) for on-demand control and prevention of bleeding episodes, management of bleeding following surgery and as a routine preventive measure to reduce the frequency of bleeding episodes in children and adults with hemophilia B. It is […]
Genome Sequencing Uncovers New Autoimmune Syndrome
Using technology that allows scientists to read the script of a person’s DNA, scientists have found a new autoimmune disease syndrome that combines severe lung disease and arthritis.
Phase I Trial Launched for Extended Half-Life Factor VIII
Baxalta has begun a Phase I, first-inhuman clinical trial of BAX 826, a recombinant factor VIII (rFVIII) treatment for hemophilia A that uses proprietary polysialic acid (PSA) technology to extend its circulating half-life.
Key Genetic Factor Behind Autoimmune Diseases and Cancer Is Identified
Scientists at Yale have uncovered a molecular mechanism that causes variants in a specific immune response gene known as MIF (macrophage migration inhibitory factor).
